Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer.
In a phase III trial, patients with PIK3CA-mutant advanced breast cancer benefited from taking the PI3Kα inhibitor alpelisib in addition to fulvestrant endocrine therapy. The combination extended median progression-free survival, elevated response rates, and proved tolerable compared with fulvestrant plus placebo.